Articles Published in 2011

Redtree People, ICR launch learning service

Friday, November 18, 2011 12:36 PM

Redtree People and the Institute of Clinical Research (ICR) are to provide tailored training and education programs to the growing community of independent freelance clinical research professionals worldwide.

More... »

Shire partners with Shionogi to develop ADHD medicines

Friday, November 18, 2011 11:48 AM

Shire has entered into an agreement with Shionogi & Co. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan. Shionogi will pay a one time fee and share costs with Shire in exchange for rights to jointly co-develop and co-commercialize the products upon approval for the Japanese market. Specific terms of the agreement are not being disclosed. 

More... »

EFPIA launches strategy to revitalize antibiotic research

Friday, November 18, 2011 10:41 AM

EFPIA, the voice of the research-based pharmaceutical industry in Europe, welcomes the publication of the European Commission's "Strategy and Action Plan to Tackle the Threat of Antibiotic Resistance".

More... »

Chapple joins Quanticate

Friday, November 18, 2011 10:30 AM

Quanticate has named Dr. Daniel Chapple vice pesident of business development and marketing, effective immediately.  He will report to Quanticate's chairman and chief executive officer David Underwood and will be based out of Quanticate’s offices in the UK and Boston, MA. In his new role, Chapple will be responsible for working with the leadership team to further develop the Centralized Clinical Data Sciences solution which is focused on the importance of data to successfully gain approval and market new products through the use of technology coupled with highly skilled statisticians, programmers, data managers, medical writers and pharmacovigilance experts.

More... »

Kenexa partners with Eli Lilly

Thursday, November 17, 2011 03:08 PM

Kenexa, a global provider of business solutions for human resources, has reported that Eli Lilly will be using Kenexa’s global recruitment process outsourcing (RPO) services in some of the major markets where Lilly conducts business globally. The five year engagement represents Kenexa’s largest global RPO partnership, and also includes Kenexa’s onboarding, recruiting, assessment, and survey solutions and employment branding.  

More... »

Genexion selects goBalto's Tracker platform

Thursday, November 17, 2011 02:59 PM

SanFrancisco-based goBalto has entered a strategic partnership with Genexion, a CRO that has selected Tracker, goBalto's web-based clinical trials platform, for its clinical research study start-up and monitoring.

More... »

Tufts CSDD receives research grant from goBalto

Thursday, November 17, 2011 02:49 PM

San Francisco-based goBalto, a developer of new generation web-based clinical research solutions, is providing a research grant for the Tufts Center for the Study of Drug Development to benchmark the clinical trial initiation process. Currently there is virtually no industry data available on the typical process that companies follow and on the amount of time that this process takes.

More... »

Cenix, SYGNIS sign RNAi research agreement

Thursday, November 17, 2011 02:02 PM

Cenix BioScience, a discovery-stage contract research provider and technology developer, has signed a research agreement with SYGNIS Bioscience, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.

More... »

Survey: ICON Medical Imaging rated top provider

Thursday, November 17, 2011 01:14 PM

Dublin-based ICON has reported that its Medical Imaging division was rated as the top provider of imaging services according to an industry survey conducted by Blue Pyramid Consulting, an affiliate of the Avoca Group.

More... »

FDA approves high dose anti-depressant

Thursday, November 17, 2011 11:45 AM

The FDA has approved IntelGenx' lead product, CPI-300, for patients with Major Depressive Disorder. CPI-300 is a novel, high-strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL. CPI-300 is the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.

More... »